NCI Director Introduces New Era of Cancer Research
NCI Director Kimryn Rathmell evoked Taylor Swift to present her vision of the 360 era for cancer research.
NCI Director Kimryn Rathmell evoked Taylor Swift to present her vision of the 360 era for cancer research.
Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United...
Last Friday, March 8, 2019, marked another milestone in immuno-oncology: The U.S. Food and Drug Administration (FDA) announced the...
The 41st San Antonio Breast Cancer Symposium, held Dec. 4-8, drew more than 7,500 attendees from more than 90...
In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for...
Breast cancer is the most commonly diagnosed cancer in the United States. In 2018, 266,120 women and 2,550 men...
On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain...
Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers,...
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just...
Earlier this year, a study published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR),...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx)...